Back to results
US 2026/0201337 A1Published application
Pre-licensed composition and cell culture methods
AssigneeMesoblast International Sarl
InventorsSilviu ITESCU, Paul SIMMONS, Jack HAYES, Justin HORST, Fiona SEE
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to MLPSC populations and methods and cell culture media for producing the same. Such methods and media may be particularly useful for promoting pre-licensing of mesenchymal lineage precursor or stem cells (MLPSCs.
Claims64
A composition comprising:
- (i) a culture-expanded population of mesenchymal lineage precursor or stem cells (MLPSCs), wherein the MLPSCs have been culture expanded in media containing:
- IFN-gamma and/or TNF-alpha;
- and/or,
- one or more pro-inflammatory cytokines selected from the group consisting of IL-6;
- IL-8;
- IL-17A;
- MCP-1;
- MIP-1-alpha;
- MIP-1-beta;
- IP-10.
7 more elements
A cryopreserved composition comprising:
- (i) a culture-expanded population of mesenchymal lineage precursor or stem cells (MLPSCs), wherein the MLPSCs have been culture expanded in media containing newborn mammalian serum obtained no more than 21 days after birth;
- and,
- (iii) a cryopreservative.
An in vitro method for pre-licensing human mesenchymal lineage precursor or stem cells (MLPSCs), the method comprising culturing the MLPSCs in media containing:
- i. IFN-gamma and/or TNF-alpha;
- and/or, one or more pro-inflammatory cytokines selected from the group consisting of IL-6;
- IL-8;
- IL-17A;
- MCP-1;
- MIP-1-alpha;
- MIP-1-beta;
- IP-10;
- and/or,
- ii. newborn mammalian serum obtained no more than 21 days after birth.
7 more elements
A media for culturing MLPSCs, the media comprising:
- IFN-gamma and/or TNF-alpha;
- and,
- one or more pro-inflammatory cytokines, wherein the pro-inflammatory cytokines are selected from the group consisting of IL-6;
- IL-8;
- IL-17A;
- MCP-1;
- MIP-1-alpha;
- MIP-1-beta;
- IP-10.
6 more elements
Dependencies are inferred from the claim text.